ARTICLE | Clinical News
NXY-059: Began Phase I testing
December 4, 2000 8:00 AM UTC
Centaur Pharmaceuticals Inc., Sunnyvale, Calif. Product: NXY-059 Business: Neurological Therapeutic category: Neuroprotectant Target: Neurons Description: Intravenous neuroprotectant Indication: Treat...